Newsletter | March 16, 2026

03.16.26 -- Making Biologics Orally Available With Vivtex's Thomas Von Erlach, Ph.D.

FEATURED ARTICLE

Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.

On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics.

INDUSTRY INSIGHTS

How One Market Signal Reframed AI's Value In Early BioTech

Explore how transparent decision-making and operational integrity are redefining value for early-stage life science ventures, navigating the path from discovery to market.

Scalable, Strategic Manufacturing Support

See how integrated scientific teams can strengthen manufacturing performance by supporting production demands, protecting compliance, and adapting quickly to shifting priorities.

Why Choose Robotic Processing For Small Batch Aseptic Filling

Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.

Scale-Up And Production Of Key Lipids Used In mRNA Delivery Systems

Discover key strategies for overcoming challenges in the industrial-scale production of ionizable and PEG lipids to optimize mRNA vaccine formulation and address critical manufacturing requirements.

The Importance Of A Centralized Payment System In Clinical Trials

Adopt a centralized payment system to streamline financial workflows, enhance site satisfaction, and ensure compliance while supporting efficient, scalable clinical trials.

Optimizing Sialic Acid Clone Screening

While the traditional high-performance analytical methods used to evaluate glycosylation offer operators high accuracy, their throughput limitations can create time and cost constraints.